- Advanced search
- Immuno Portal
- Malaria Portal
Molecular properties generated using the CDK
|Compound class||Synthetic organic|
|Approved drug?||Yes (FDA (2019))|
|International Nonproprietary Names|
|BAF-312 | BAF312 | compound 32 [PMID: 24900670] | Mayzent®|
|Pharmacologically, siponimod (BAF312) is a selective sphingosine-1-phosphate (S1P) receptor agonist, with some selectivity for the S1P1 and S1P5 receptor isoforms . It is an orally active drug. Siponimod was developed by Novartis for secondary progressive multiple sclerosis (SPMS), originally as a back-up compound for fingolimod. Compared to fingolimod it has more favourable pharmacokinetics.
Novartis announced positive results from their Phase 3 EXPAND study (BAF312 versus placebo) in SPMS (August 2016- link to announcement here).
The SIPR signalling pathway is important in autoimmune biology.
|CAS Registry No.||1230487-00-9 (source: WHO INN record)|
|GtoPdb PubChem SID||318164808|
|Search Google for chemical match using the InChIKey||KIHYPELVXPAIDH-HNSNBQBZSA-N|
|Search Google for chemicals with the same backbone||KIHYPELVXPAIDH|
|Search PubMed clinical trials||siponimod|
|Search PubMed titles||siponimod|
|Search PubMed titles/abstracts||siponimod|
|Search UniChem for chemical match using the InChIKey||KIHYPELVXPAIDH-HNSNBQBZSA-N|
|Search UniChem for chemicals with the same backbone||KIHYPELVXPAIDH|